Objective We aim to investigate the efficacy and safety of calcium dobesilate in the treatment of hyperkalemia in chronic kidney disease patients. Methods Chronic kidney disease patients complicated with hyperkalemia(5.50~6.80mmol/L)in 21 cases of non-dialysis patients treated with oral kayexalate treatment:5g/ times,3 times/d. 5 cases of them received the therapy:5g/ times,1~2 times /d,because they had a urinary volume more than 1000ml. Results 21 cases of non-dialysis patients with a high potassium level(6.09±0.33)mmol/L. After the treatment of kayexalate,serum potassium levels dropped to(5.19±0.38)mmol/L,compared with the baseline values,the difference was statistically significant (P<0.01). 5 patients received small dose of kayexalate as a maintain treatment,serum potassium levels fell to(4.67±0.30)mmol/L after 1 week. Conclusion Oral calcium dobesilate can be used as an effective treatment for hyperkalemia in CKD non dialysis patients. Oral administration of low dose calcium polystyrene sulfonate can stabilize the blood potassium level and prevent hyperkalemia.%目的 探讨聚苯乙烯磺酸钙在慢性肾脏病(CKD)非透析患者降钾治疗中的有效性及安全性.方法 CKD合并高钾血症(5.50~6.80mmol/L)的非透析患者21例,给予口服聚苯乙烯磺酸钙治疗,5g/次,3次/d,分别观察服药后24h,48h后患者的血钾变化.其中5例尿量维持>1000ml的CKD非透析患者血钾稳定后给予维持性聚苯乙烯磺酸钙治疗,5g/次,1~2次/d.观察血钾变化.结果 21例CKD非透析患者合并肾性高钾(6.09±0.33)mmol/L,口服聚苯乙烯磺酸钙治疗24h后血钾水平降至(5.19±0.38)mmol/L,与基线值比较,差异有统计学意义(P<0.01).5例CKD非透析患者接受小剂量聚苯乙烯磺酸钙维持治疗,随访1周,血钾水平降至(4.67±0.30)mmol/L.结论 口服聚苯乙烯磺酸钙可以作为一种CKD非透析患者发生高钾血症的有效治疗方案.小剂量聚苯乙烯磺酸钙口服治疗可达到稳定患者血钾水平,预防高钾血症的作用.
展开▼
